Mogrify

Mogrify is a private, pre-clinical stage biotech developing in vivo cellular reprogramming therapies using its proprietary MOGRIFY® and epiMOGRIFY® platforms. These platforms systematically identify the transcriptomic and epigenetic switches required to convert one cell type into another, aiming to regenerate tissues damaged by disease or injury. Founded on foundational research published in high-impact journals, the company has raised significant venture capital and is led by an experienced team including CEO Dr. Darrin M. Disley, OBE. Its approach represents a potentially disruptive modality within the cell and gene therapy sector.

Proprietary suite of platforms for direct cellular reprogramming. MOGRIFY® uses transcriptomic data to identify transcription factor combinations for cell conversion. epiMOGRIFY® uses epigenetic data to identify factors to maintain cell identity and support reprogramming in defined media.

Mogrify operates in the competitive field of cellular reprogramming and regenerative medicine, facing potential competition from other biotechs exploring transdifferentiation, stem cell-derived therapies, and gene editing. Its key differentiator is its systematic, data-driven platform to predict reprogramming factors, as opposed to empirical discovery. It also competes for funding and talent within the broader cell and gene therapy sector.